Article

Alpha blockers have modest effect in pelvic pain Tx

Author(s):

Emma Hitt, PhD

Chicago-Two alpha blockers appear to have modest efficacy in treatingchronic prostatitis/chronic pelvic pain syndrome, according to separatestudies presented here at the AUA annual meeting.

Related Videos
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Patient talking with doctor | Image Credit: © bongkarn - stock.adobe.com
Shaya Taghechian, MD, answers a question during a video interview
doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
Raveen Syan, MD, FPMRS, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Cassandra K. Kisby, MD, MS, answers a question during a Zoom video interview
Vikas Desai, MD, answers a question during a Zoom video interview
Related Content
Vaginal estrogen for GSM not associated with major adverse cardiovascular events
October 28th 2024

Vaginal estrogen for GSM not associated with major adverse cardiovascular events

Hannah Clarke
“These findings support the safety of vaginal estrogen for treatment of local menopause symptoms, even in high-risk women,” says Gabriella M. Rustia, MD.
Speaking of Urology: Dr. Winter on the use of vaginal estrogen
July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff
In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.
Collaboration to advance market launch of ProVate device for pelvic organ prolapse
September 6th 2024

Collaboration to advance market launch of ProVate device for pelvic organ prolapse

Hannah Clarke
The company expects the device to become available for US patients with pelvic organ prolapse in September 2024.
Dr. Malik evaluates quality of Reddit content on recurrent UTIs
March 17th 2022

Dr. Malik evaluates quality of Reddit content on recurrent UTIs

Urology Times staff
“I think we as urologists have to be proactive in providing information to our patients so that they avoid financial harm and potentially bodily harm from this sort of misinformation,” says Rena D. Malik, MD.
National Urogynecology Research Agenda: A Path Forward for Advancing the Treatment and Management of Pelvic Floor Disorders
March 25th 2024

National Urogynecology Research Agenda: A Path Forward for Advancing the Treatment and Management of Pelvic Floor Disorders

American Urogynecologic Society
Developed by the AUGS Scientific Committee and Research Agenda Writing Group
FDA approves cefepime/enmetazobactam for complicated UTI
February 27th 2024

FDA approves cefepime/enmetazobactam for complicated UTI

Hannah Clarke
The FDA approval is supported by data from the phase 3 ALLIUM trial, which demonstrated the non-inferiority and superiority of cefepime/enmetazobactam vs piperacillin/tazobactam.
© 2024 MJH Life Sciences

All rights reserved.